Overview
- Bioventus reported second‑quarter revenue of $153 million, a 4% rise, with adjusted EBITDA of $35 million and adjusted EPS of $0.22.
- The company reaffirmed full‑year 2026 guidance of $600 million–$610 million in revenue and $0.75–$0.79 in adjusted EPS.
- After the quarter the board formed an independent committee and retained Evercore to evaluate multiple expressions of interest including an unsolicited acquisition proposal, but offered no details or timeline.
- Bioventus reduced debt by $24 million in the quarter, lowering net leverage to below two times and increasing flexibility to fund growth or enhance its attractiveness in a sale process.
- Management said it will boost investment in platelet‑rich plasma, peripheral nerve stimulation, Ultrasonics and international expansion and expects those initiatives to accelerate revenue contributions in the second half of 2026.